Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07756281
Recruiting Phase 1

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

NCT07756281 · tracked via the Priya Life Science USA tracker
Sponsor
ParVation Therapeutics, Inc
Phase
Phase 1
Started
2026-09-01
Last updated
2026-10-27

Condition(s) studied

Pancreatic CancerPancreatic Acinar Carcinoma

Investigational drug(s) / intervention(s)

SNV1521 →daraxonrasib →

SNV1521: SNV1521 is an oral investigational anticancer drug. In this study, SNV1521 is administered at different dose levels together with the RAS inhibitor daraxonrasib in adults with locally advanced unresectable or metastatic pancreatic cancer.

daraxonrasib: Daraxonrasib is an oral targeted cancer medicine used in this study together with SNV1521. It is given once daily to help evaluate the safety and tolerability of the drug combination in people with advanced pancreatic cancer.

Study summary

This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (18 years and older). * Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. * Cancer confirmed by tissue or cell examination (histology or cytology). * At least one measurable tumor on scans. * Good enough general health and organ function to receive study treatment, as judged by the study doctor. * Able to swallow oral medicines. * Willing to follow study visit schedule and contraception requirements. Exclusion Criteria: * Serious heart, lung, liver, or other medical problems that would make study treatment unsafe. * Active, uncontrolled infections. * Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated). * Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions). * Known brain or nervous system involvement from the cancer that is not stable or controlled. * Pregnant or breastfeeding, or unwilling to use required birth control during and after the study.

Primary outcome measure(s)

  • Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities — through study completion, an average of 1 year
    Number, type, and severity of treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities in participants receiving SNV1521 plus daraxonrasib, used to identify doses suitable for further study, classified and graded according to CTCAE v6.0 and protocol-defined DLT criteria

Trial sites (1)

FacilityCityRegionStatus
MD Anderson Houston Texas Recruiting

More ParVation Therapeutics, Inc. trials in the USA

SNV1521 in Participants With Advanced Solid Tumors Recruiting

Other trials for the same condition

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Recruiting
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma Recruiting
A Study Evaluating a New Radiation Treatment Workflow (NGDS) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07756281 on ClinicalTrials.gov ↗ ← All trials in the USA